Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

As reproductive health access becomes increasingly restricted across the country, expanding Washington’s law that protects ...

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Guardant Health (GH – Research Report), with a price target ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...

Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...

Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...

It's smart for parents to ask questions, but "the overwhelving evidence tells us vaccines are safe, effective and critical," ...

Principal Financial Group Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 8.0% in ...